Vudalimab

Vudalimab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Xencor, Inc., in ovarian cancer, endometrial cancer, cervical cancer, prostate cancer. A bispecific antibody, as described in the registry record: one molecule binds two different targets, most often a tumour antigen and an immune cell or a second tumour pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.